Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide
Key facts
Active substance |
|
Therapeutic area |
Cardiovascular diseases
|
Decision number |
P/227/2009
|
PIP number |
Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Essential hypertension
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|